-
1
-
-
34247140972
-
Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: Children's Cancer Group (CCG) 7943
-
Seibel NL, Krailo M, Chen Z, et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. Cancer. 2007;109:1646-1653.
-
(2007)
Cancer
, vol.109
, pp. 1646-1653
-
-
Seibel, N.L.1
Krailo, M.2
Chen, Z.3
-
2
-
-
33644505791
-
Prognostic factors for osteosarcoma of the extremity trerated with neoadjuvant chemotherapy: 15-Year experience in 789 patients treated at a single institution
-
DOI 10.1002/cncr.21724
-
Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-1161. (Pubitemid 43297356)
-
(2006)
Cancer
, vol.106
, Issue.5
, pp. 1154-1161
-
-
Bacci, G.1
Longhi, A.2
Versari, M.3
Mercuri, M.4
Briccoli, A.5
Picci, P.6
-
4
-
-
32044438250
-
A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma
-
DOI 10.1002/pbc.20562
-
McTiernan A, Meyer T, Michelagnoli MP, Lewis I, Whelan JS. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. Pediatr Blood Cancer. 2006;46:345-350. (Pubitemid 43201851)
-
(2006)
Pediatric Blood and Cancer
, vol.46
, Issue.3
, pp. 345-350
-
-
McTiernan, A.1
Meyer, T.2
Michelagnoli, M.P.3
Lewis, I.4
Whelan, J.S.5
-
5
-
-
23844490154
-
Metastatic osteosarcoma at diagnosis: Prognostic factors and long-term outcome - The French pediatric experience
-
DOI 10.1002/cncr.21263
-
Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome - the French pediatric experience. Cancer. 2005;104:1100-1109. (Pubitemid 41170240)
-
(2005)
Cancer
, vol.104
, Issue.5
, pp. 1100-1109
-
-
Mialou, V.1
Philip, T.2
Kalifa, C.3
Perol, D.4
Gentet, J.-C.5
Marec-Berard, P.6
Pacquement, H.7
Chastagner, P.8
Defaschelles, A.-S.9
Hartmann, O.10
-
6
-
-
12944305738
-
Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only
-
DOI 10.1097/01.mph.0000150739.73067.f3
-
del Prever AB, Fagioli F, Berta M, Bertoni F, Ferrari S, Mercuri M. Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only. J Pediatr Hematol Oncol. 2005;27:42-45. (Pubitemid 40175961)
-
(2005)
Journal of Pediatric Hematology/Oncology
, vol.27
, Issue.1
, pp. 42-45
-
-
Del Prever, A.B.1
Fagioli, F.2
Berta, M.3
Bertoni, F.4
Ferrari, S.5
Mercuri, M.6
-
7
-
-
0038688477
-
Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
-
Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011-2018.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2011-2018
-
-
Kager, L.1
Zoubek, A.2
Potschger, U.3
-
8
-
-
0041700123
-
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: Recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide
-
Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003;14:1126-1134.
-
(2003)
Ann Oncol
, vol.14
, pp. 1126-1134
-
-
Bacci, G.1
Briccoli, A.2
Rocca, M.3
-
9
-
-
0027406653
-
Osteogenic sarcoma with clinically detectable metastasis at initial presentation
-
Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993;11:449-453. (Pubitemid 23071040)
-
(1993)
Journal of Clinical Oncology
, vol.11
, Issue.3
, pp. 449-453
-
-
Meyers, P.A.1
Heller, G.2
Healey, J.H.3
Huvos, A.4
Applewhite, A.5
Sun, M.6
Laquaglia, M.7
-
10
-
-
0027383879
-
Liposome-encapsulated MTP-PE: A novel biologic agent for cancer therapy
-
Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol. 1993;14:286-292.
-
(1993)
J Immunother Emphasis Tumor Immunol
, vol.14
, pp. 286-292
-
-
Asano, T.1
Kleinerman, E.S.2
-
11
-
-
0024359271
-
Therapy for osteosarcoma in dogs with intravenous injection of liposome- encapsulated muramyl tripeptide
-
MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome- encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989;81:935-938.
-
(1989)
J Natl Cancer Inst
, vol.81
, pp. 935-938
-
-
MacEwen, E.G.1
Kurzman, I.D.2
Rosenthal, R.C.3
-
12
-
-
0026631061
-
Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration
-
Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992;10:1310-1316.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1310-1316
-
-
Kleinerman, E.S.1
Jia, S.F.2
Griffin, J.3
Seibel, N.L.4
Benjamin, R.S.5
Jaffe, N.6
-
13
-
-
0027347270
-
Liposome-encapsulated muramyl tripeptide: A new biologic response modifier for the treatment of osteosarcoma
-
Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993;62:101-107.
-
(1993)
Cancer Treat Res
, vol.62
, pp. 101-107
-
-
Kleinerman, E.S.1
Maeda, M.2
Jaffe, N.3
-
14
-
-
20244387692
-
Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: A progress review
-
MacEwen EG, Kurzman ID, Helfand S, et al. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target. 1994;2:391-396.
-
(1994)
J Drug Target
, vol.2
, pp. 391-396
-
-
MacEwen, E.G.1
Kurzman, I.D.2
Helfand, S.3
-
15
-
-
0029125936
-
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide
-
Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995;9:927-938.
-
(1995)
Hematol Oncol Clin North Am
, vol.9
, pp. 927-938
-
-
Kleinerman, E.S.1
-
16
-
-
0028928375
-
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma
-
Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995;18:93-99.
-
(1995)
Am J Clin Oncol
, vol.18
, pp. 93-99
-
-
Kleinerman, E.S.1
Gano, J.B.2
Johnston, D.A.3
Benjamin, R.S.4
Jaffe, N.5
-
17
-
-
0028997131
-
Combination therapy with ifosfamide and liposome- encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation
-
Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome- encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol. 1995;17:181-193.
-
(1995)
J Immunother Emphasis Tumor Immunol
, vol.17
, pp. 181-193
-
-
Kleinerman, E.S.1
Meyers, P.A.2
Raymond, A.K.3
Gano, J.B.4
Jia, S.F.5
Jaffe, N.6
-
18
-
-
0032916105
-
In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells
-
Kurzman ID, Shi F, Vail DM, MacEwen EG. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm. 1999;14:121-128.
-
(1999)
Cancer Biother Radiopharm
, vol.14
, pp. 121-128
-
-
Kurzman, I.D.1
Shi, F.2
Vail, D.M.3
MacEwen, E.G.4
-
19
-
-
33745492007
-
Liposomal muramyl tripeptide phosphatidyl ethanolamine: Ifosfamide-containing chemotherapy in osteosarcoma
-
DOI 10.2217/14796694.2.3.333
-
Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol. 2006;2:333-343. (Pubitemid 43960105)
-
(2006)
Future Oncology
, vol.2
, Issue.3
, pp. 333-343
-
-
Anderson, P.1
-
20
-
-
33745642092
-
Novel therapeutic approaches in pediatric and young adult sarcomas
-
Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep. 2006;8:310-315. (Pubitemid 43970983)
-
(2006)
Current Oncology Reports
, vol.8
, Issue.4
, pp. 310-315
-
-
Anderson, P.M.1
Pearson, M.2
-
21
-
-
33645828043
-
Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma
-
Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets. 2006;6:123-133.
-
(2006)
Curr Cancer Drug Targets
, vol.6
, pp. 123-133
-
-
Nardin, A.1
Lefebvre, M.L.2
Labroquere, K.3
Faure, O.4
Abastado, J.P.5
-
22
-
-
39149136228
-
Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
-
Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633-638.
-
(2008)
J Clin Oncol
, vol.26
, pp. 633-638
-
-
Meyers, P.A.1
Schwartz, C.L.2
Krailo, M.D.3
-
23
-
-
20144380941
-
Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
-
Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2004-2011
-
-
Meyers, P.A.1
Schwartz, C.L.2
Krailo, M.3
-
25
-
-
0242440867
-
Osteosarcoma Necrosis Following Chemotherapy: Innate Biology Versus Treatment-Specific
-
DOI 10.1097/00043426-200311000-00003
-
Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol. 2003;25:840-841. (Pubitemid 37413831)
-
(2003)
Journal of Pediatric Hematology/Oncology
, vol.25
, Issue.11
, pp. 840-841
-
-
Gorlick, R.1
Meyers, P.A.2
-
26
-
-
0031861214
-
Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol
-
Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452-2458. (Pubitemid 28309040)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.7
, pp. 2452-2458
-
-
Meyers, P.A.1
Gorlick, R.2
Heller, G.3
Casper, E.4
Lane, J.5
Huvos, A.G.6
Healey, J.H.7
-
27
-
-
12244289913
-
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders
-
DOI 10.1016/S0959-8049(02)00747-5, PII S0959804902007475
-
Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488-494. (Pubitemid 36173693)
-
(2003)
European Journal of Cancer
, vol.39
, Issue.4
, pp. 488-494
-
-
Smeland, S.1
Muller, C.2
Alvegard, T.A.3
Wiklund, T.4
Wiebe, T.5
Bjork, O.6
Stenwig, A.E.7
Willen, H.8
Holmstrom, T.9
Folleras, G.10
Brosjo, O.11
Kivioja, A.12
Jonsson, K.13
Monge, O.14
Saeter, G.15
|